Research programme: metabolite replacement therapeutics - TM3 Therapeutics

Drug Profile

Research programme: metabolite replacement therapeutics - TM3 Therapeutics

Alternative Names: Acetyl-4’-phosphopantetheine; P-PantSAc; TM-1803

Latest Information Update: 18 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TIRCON
  • Developer TIRCON; TM3 Therapeutics; University Medical Center Groningen
  • Class Neuroprotectants
  • Mechanism of Action Phosphopantothenate replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pantothenate kinase-associated neurodegeneration
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Pantothenate kinase-associated neurodegeneration

Most Recent Events

  • 13 Sep 2017 Preclinical trials in Pantothenate kinase-associated neurodegeneration in Netherlands and USA (unspecified route)
  • 13 Sep 2017 Research programme: metabolite replacement therapeutics - TM3 Therapeutics receives Orphan Drug status for Pantothenate kinase-associated neurodegeneration in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top